Inappropriate sinus tachycardia, also known as IST, is a condition of elevated sinus rate unassociated with known pathological, pharmacological, or physiological causes. Its diagnosis has been, in the past, missed or at times dismissed. It does not help that its definitions in current literature are inconsistent, and professional society consensus have had limited impact. Considering its broad setting of physiology, pathology, and uncertainties, the therapy for IST remains challenging. To date high rates of symptom recurrence, treatment failure, and complications have followed many therapies.

Although, not well accepted by guidelines, the main hope lies in ablation procedures. Unfortunately, the results of endocardial radiofrequency ablation have not been encouraging. Today we will explore the multiple aspects of IST and the treatment techniques surrounding it.

Presenters:

Steven Hoff, M.D., a board-certified cardiac and thoracic surgeon at Baptist Health Miami Cardiac & Vascular Institute

Mario Pascual, M.D., an electrophysiologist with Baptist Health Miami Cardiac & Vascular Institute specializing in diagnosing arrhythmias and treating heart rhythm disorders

We could not be more exhilarated about the research led by investigators at Baptist Health Miami Cancer Institute. Several of our physician-researchers presented their studies at this year’s ASCO annual meeting in Chicago. Join us as we highlight many of our findings, because many of these landmark studies are transforming care, extending lives, and improving the quality of life of our patients.

Presenters:

Michael Zinner, M.D., Executive Medical Director of Baptist Health Miami Cancer Institute

Manmeet Ahluwalia, M.D., Chief of Medical Oncology, Chief Scientific Officer, Deputy Director of Miami Cancer Institute, and Fernandez Family Foundation Endowed Chair in Cancer Research

Even with the success of reducing smoking, lung cancer remains the leading cause of cancer deaths worldwide for both men and women. In 2023, there were approximately 238,000 new lung cancers and 125,000 deaths in the United States alone. In recent decades, the evolution of robotic-assisted thoracic surgery has enhanced primary lung cancer treatment and postoperative outcomes. This, in combination with advances in immunotherapy and our understanding of cancer’s molecular biology, brings many tools to the battle against the leading cause of cancer deaths in the United States.

Join Dr. Mark Dylewski, chief of general thoracic surgery at Baptist Health, and Dr. Paul Kaywin, medical oncologist at Baptist Health Miami Cancer Institute, as they discuss advances in lung cancer treatment from a medical oncology and surgical perspective.

Mark Dylewski, M.D.

Director of General Thoracic Surgery and Robotic Thoracic Surgery

Chief of General Thoracic Surgery, Baptist Health

Chairman of Thoracic Surgical Oncology, Miami Cancer Institute

Paul Kaywin, M.D.

Medical Oncologist

Miami Cancer Institute

Baptist Health